Don't Have Time For A Big Workout? Try 'Exercise Snacking'
After a long day at work, the last thing you may want to do is a hard workout. Even thinking about it can be exhausting, especially when you're trying to balance that with dinner, spending time with family and friends and other things on your to-do list. How can you possibly do it all?
That's where 'exercise snacking' comes in. Instead of doing one big workout a day, it encourages you to get in some movement throughout the day in shorter bursts.
The goal is to move your body in a way that feels good or productive to you. Exercise snacking can be as informal or formal as you'd like. On the informal side, it might look like walking your dog, stretching your legs, doing jumping jacks while watching TV, taking the stairs or using a resistance band while you're at work.
'You are able to do these without it really impacting the time in your day,' said Joslyn Thompson-Rule, a Peloton instructor.
Exercise snacking is not only easier to fit into a busy schedule, but it's beneficial for your health, too.
According to a 2019 study in Journal of Aging Research, exercise snacking can improve leg muscle function and size. And even climbing the stairs for a few minutes throughout the day can improve cardiovascular health, according to research at McMaster University and UBC Okanagan.
Exercise snacking can improve your daily living, too. It 'gives you energy bursts' and 'improves sleep performance,' said Georgy Dillon, a pre- and postnatal personal trainer who uploads exercise snack videos. So, it can help you fight that afternoon slump you may feel after lunch.
'Of course this is great for cardiovascular health, but the big thing for me is the positive impact it has on mental health, too,' Thompson-Rule said. If you feel down, unmotivated or unable to focus, fitting in an exercise snack can change that. According to Dillon, it improves clarity, elevates your mood and just generally benefits your mental well-being.
Since it's usually easier to fit this type of exercise in, it can also help you feel more accomplished, like you're able to meet your goals. '[It's] rewarding and gives you a sense of achievement,' Dillon added.
For people who have had an exercise addiction, knowing what a 'healthy' workout looks like and stopping when necessary can be difficult. Exercise snacking is purposefully short, which can be less triggering and feel more natural than a trip to the gym.
'For those who have a condition or find working out more difficult, practicing the appropriate small exercise snacks means that they aren't putting themselves under too much pressure too soon,' Dillon said.
For people with a chronic illness, such as back pain or a heart issue, exercise isn't always an option — especially for a long stretch of time. Talking to your doctor is best (preferably one who's well-versed in Health at Every Size, a holistic framework that promotes health equity), but according to the Cleveland Clinic, low-impact exercises such as walking or resistance bands for a short period can be the 'snack' to choose. But again, ask your physician first (and listen to your body), as more exercise can make things worse for people with chronic fatigue syndrome, for example.
So think about what you want exercise snacks to look like for you. What fits into your day best and is most doable?
'There are no hard and fast rules — again, we are trying to move away from the idea that you have to move for a certain period of time for it to 'count,'' Thompson-Rule said.
But if you need some more formal ideas to get you started, one option Dillon suggested is an interval workout. 'Choose four exercises and set an interval timer to do 30 seconds of exercise, 20 seconds of rest and repeat for the exercise snack time, [such as] eight minutes,' she said.
Those exercises could be pushups, situps, squats, planks, lunges or whatever you find most enjoyable. (Remember: If you don't enjoy it, you won't want to do it, and creating a habit will be harder. Plus, you deserve to enjoy it. Exercise doesn't have to be something you dread!)
Thompson-Rule agreed. 'With that in mind, meeting yourself where you are at with both time and movement means you get to do what works for you,' she said.
Ultimately, exercise snacking is a whole new (and maybe even better) way to look at exercise. 'It moves us away from the idea that you have to work out for a certain amount of time for it to be effective,' Thompson-Rule added. 'Working out is so different for everyone.'
Don't have a lot of time to work out, but want to squeeze some movement in? These are fitness experts' top recommended products!
HuffPost may receive a share from purchases made via links on this page. Every item is independently selected by the HuffPost Shopping team. Prices and availability are subject to change.
Amazon
"Jump ropes are not only a great way to work on your coordination and footwork, but can also be used for a variety of cardio and HIIT workouts to get your heart rate up," explained Belgrave. Our pick: This model has ball bearings for tangle-free use.
$8.99 at Amazon
Amazon
If working from home is an option, then the addition of a standing desk and walking pad can be an absolute game-changer — and my colleague Lindsay Holmes swears by this one."If you're sedentary, think of ways to add standing or moving throughout the day to build a base of strength and cardio. If you work at a desk, you can get a walking pad to get your steps in while taking meetings instead of sitting," Goodtree told HuffPost.
$799 at Amazon
Amazon
Goodtree recommended glider discs to level up a workout without pricey, bulky equipment. They're compact, easy to tuck away, can be used on carpet or hardwood floors, and make it easy to squeeze in intense, low-impact workouts. They're great for core workouts as well as lunges and much more. This two-pack from Elite Core Sliders is available in four different colors.
$11.99+ at Amazon
Amazon
All of our experts recommended resistance bands, and Hughes pointed to Therabands as a great option for stretching, physical therapy exercises and toning. They're easy to use, tuck away and feature color-coded resistance levels. Their wider band size makes them easier to use for exercises like squats and ab work.
$14.99 at Amazon
Amazon
Hughes considers a basic set of resistance bands such as this one to be a great bare minimum baseline for the fitness averse. This set of five ranges from extra light to extra heavy resistance, so you can work your way up as your strength increases. You can even keep them in your purse so you can pop one on and start doing some squats while out and about. Stranger things have happened!
$12.95 at Amazon
Amazon
Hughes pointed to superbands as another handy resistance band option. These have a heavier resistance than the other bands mentioned, but also come in a variety of different resistances, so you can move at your own pace. "You can easily increase the difficulty with a heavier-tension band (with minimal space and finances being used)," Hughes noted.
$18.99+ at Amazon
Amazon
Goodtree has this variable set from Bowflex that replaces 15 sets of weights! They're adjustable from five to 52 pounds each, so you can use this space-saving, versatile dumbbell for a range of exercises and strength levels. It even has motion-tracking technology that can count your reps and track your form when used in conjunction with a smart device's camera.
$214.97 at Amazon
Amazon
According to Belgrave, "a fitness tracker can help workout-averse people keep track of their daily activity and motivate them to move more. Many fitness trackers come with features like step tracking, heart rate monitoring, and reminders to get up and move throughout the day."You can set goals and reminders and track your progress with this super popular Fitbit fitness tracker. It's surprisingly subtle and chic, and will help motivate you to get some movement in whenever you have a spare moment.
$55 at Amazon (originally: $99.99)
Amazon
Hughes and Goodtree both recommended having a designated exercise mat regardless of what kind of workout you choose. Hughes noted that "it can help create space, a time and place for your workout to occur, providing motivation both physically and mentally.Our pick: This extra-thick, high-density workout mat can be used for everything from yoga and mat pilates to bodyweight exercises, weight lifting and more. It's durable and strong, made with anti-tear foam with excellent slip resistance.
$22.56 at Amazon
Amazon
If mobility issues, fear of injury or stiffness is keeping you from fully embracing a workout, then a yoga block might help add stability and ease your mind. Hughes pointed out that yoga blocks can also be helpful because they can be used to create an incline and for slow eccentric movements. Use them under your chest to make progress with push-ups or tuck them between your knees to create tension.Our pick: This version from Gaiam has a small footprint and can be used in a wide variety of workouts. It provides stability, support and balance, and is made with latex-free EVA foam with a soft non-slip surface.
$14.99 at Amazon
Amazon
A small set of dumbbells make it easy to get motivated and squeeze in a quick workout. "As you get more into the workout flow, a range of dumbbells is always helpful. An external load can help maximize the difficulty of time spent under tension, improving lean muscle mass development," Hughes explained.This simple set of three different weights includes its own stand, so you don't have to worry about storage.
$38.20 at Amazon
Amazon
A foam roller can help you indulge in a bit of post-workout massage and relaxation. Feeling good will help you want to stay consistent."Foam rollers are the best piece of equipment for a self-message. They can be used to release tight muscles, improve mobility, and reduce soreness after a workout," Belgrave pointed out.You can try this lightweight roller from Amazon Basics, made of molded polypropylene to keep its firmness.
$16.75 at Amazon
Amazon
Throw these on your ankles or wrists while doing chores around the house, chasing your kids around or running errands for a bit of increased resistance without having to carve out additional time for a workout. You'll be surprised how much of a difference just one pound each can make. I love them, and Goodtree also finds they're an easy way to add a bit of extra oomph.
$64+ at Amazon
9 Habits That Can Drastically Improve Your Heart Health
7 Heart-Healthy Activities That Have Nothing To Do With Traditional Cardio
5 Exercises You Should Do In The Morning, According To Experts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
31 minutes ago
- Medscape
Fewer ECG Abnormalities in Early T2D With Combo Therapy
TOPLINE: In patients with type 2 diabetes (T2D) of less than 10 years' duration who were taking metformin monotherapy, ECG abnormalities — including evidence of cardiovascular autonomic neuropathy — were common and associated with cardiovascular risk factors. After adding one of four frequently used glucose-lowering agents to metformin, fewer major ECG changes occurred with liraglutide than with the other treatments. METHODOLOGY: Researchers aimed to examine ECG abnormalities and cardiovascular autonomic neuropathy across the different glucose-lowering treatment groups in 5029 participants (mean age, 57.2 years; diabetes duration, 4.2 years; A1c level, 7.5%; 36.4% women) from the GRADE trial. The participants had T2D for less than 10 years and were initially taking metformin monotherapy before being randomly assigned to receive metformin plus one of four commonly used glucose-lowering agents (insulin glargine, glimepiride, liraglutide, or sitagliptin). Patients were followed up for an average of 5 years. Resting ECGs were recorded at baseline and at 2‐ and 4‐year follow-ups and analyzed for overall, major, and minor abnormalities, as well as heart rate variability — a measure of cardiovascular autonomic neuropathy. TAKEAWAY: More than half of participants in the GRADE trial had ECG abnormalities (57.1%) and ECG-defined cardiovascular autonomic neuropathy (52.8%) at baseline. The presence of these abnormalities was associated with longer diabetes duration, higher systolic blood pressure, greater prevalence of hyperlipidemia, more frequent use of lipid-lowering treatment, and beta-blocker use. Major ECG abnormalities occurred less frequently in the liraglutide group than in the other treatment groups (9% vs 13% at 4 years). Researchers found no significant differences in ECG-defined cardiovascular autonomic neuropathy between the liraglutide and non-liraglutide groups at 2 and 4 years (P = .42). IN PRACTICE: "ECG abnormalities, including those of CAN [cardiovascular autonomic neuropathy], are common in T2D < 10 years and are associated with certain CV [cardiovascular] risk factors. The development of major ECG abnormalities may differ by glucose-lowering treatment, as fewer occurred with liraglutide vs the other treatments," the authors concluded. SOURCE: The study was led by Rodica Pop-Busui, MD, PhD, Oregon Health & Science University in Portland. The results were presented on June 20 at the American Diabetes Association (ADA) 85th Scientific Sessions, being held June 20-23 at the McCormick Place Convention Center in Chicago, Illinois. LIMITATIONS: This abstract did not discuss any limitations. DISCLOSURES: Some authors disclosed receiving research support, consulting fees; serving on boards, advisory panels; being stock/shareholders; or other relationships with pharmaceutical and diagnostics companies and institutions. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025. Simultaneously, results from QWINT-1, a first-of-its-kind fixed-dose study, were published in The New England Journal of Medicine, while results from QWINT-3 and QWINT-4 were published in The Lancet. In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.1,2 In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.3 In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand.4 In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine at week 26 for the efficacy estimand.5 In these two trials, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, which consisted of only four single-dose titration options, has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes," said Dr. Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator for QWINT-1. "A simpler, once-weekly regimen with efsitora may help people with type 2 diabetes initiate and manage insulin therapy with the goal of improving blood sugar levels. Across all QWINT trials, the results showed that once-weekly efsitora controlled glucose as effectively as the most popular once-daily basal insulins." QWINT-1 Primary EndpointEfficacy Estimand Treatment-RegimenEstimand6 Primary Endpoint – A1C Reduction (Resulting A1C) at Week 52 Efsitora -1.31 % (6.92 %) -1.19 % (7.05 %) Glargine -1.27 % (6.96 %) -1.16 % (7.08 %)QWINT-3 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-RegimenEstimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -0.86 % (6.93 %) -0.81 % (6.99 %) Degludec -0.75 % (7.03 %) -0.72 % (7.08 %) Key Secondary Endpoint – Rates of Clinically Significant or Severe Nocturnal Hypoglycemic Events Per Patient-Year of Exposure up to Week 787,8 Efsitora 0.11 Degludec 0.10 Key Secondary Endpoint – Percent Time in Range (70-180 mg/dL) During the FourWeeks Prior to Week 26 Efsitora 62.8 % 61.4 % Degludec 61.3 % 61.0 %QWINT-4 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-Regimen Estimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -1.07 % (7.12 %) -1.01 % (7.17 %) Glargine -1.07 % (7.11 %) -1.00 % (7.18 %) Key Secondary Endpoint – Participants Achieving A1C <7% at Week 26 Without Nocturnal Hypoglycemia Efsitora 39.5 % 38.6 % Glargine 36.6 % 35.9 % Key Secondary Endpoint – Rates of Clinically Significant or Severe NocturnalHypoglycemic Events Per Patient-Year of Exposure up to Week 26 Efsitora 0.67 Glargine 1.00 "Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," said Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly. "These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach. We look forward to working with regulatory agencies to bring this innovation to patients around the world." Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for the treatment of type 2 diabetes. In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks. In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with efsitora vs. 5.9 with insulin glargine at 26 weeks. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year. About the QWINT clinical trial programThe QWINT Phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 3,000 people living with type 2 diabetes across four global registration studies. QWINT-1 (NCT05662332) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin using a fixed dose escalation to daily insulin glargine for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 795 participants across the U.S., Argentina and Mexico to receive efsitora once weekly or insulin glargine once daily, administered subcutaneously. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to daily use of insulin glargine. QWINT-3 (NCT05275400) was a multicenter, randomized, parallel-design, open-label trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 78 weeks after a three-week lead-in followed by a five-week safety follow up period, in adults with type 2 diabetes who are currently treated with basal insulin. The trial randomized 986 participants across the U.S., Argentina, Hungary, Japan, Korea, Poland, Puerto Rico, Slovakia, Spain and Taiwan to receive efsitora once weekly or insulin degludec once daily, administered subcutaneously. The primary objective of the study was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin degludec. QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine. About insulin efsitora alfaInsulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. P-LLY The efficacy estimand represents the treatment effect on all participants who adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia. From a baseline of 8.20% for efsitora and 8.28% for insulin glargine. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. From a baseline of 7.80% for both efsitora and insulin degludec. From a baseline of 8.18% for both efsitora and insulin glargine. The treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation or introduction of rescue therapy for persistent severe hyperglycemia. Blood glucose <54 mg/dL. Nocturnal hypoglycemia was defined as any event that occurred at night between midnight and 6 a.m. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Niki Biro; niki_biro@ 317-358-9074 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
an hour ago
- CBS News
Annual Fight For Air Climb at Soldier Field raises over $350K for lung health
Despite the heat in Chicago, climbers took to Soldier Field for the annual Fight For Air Climb event to raise thousands of dollars for lung health. Over 700 people from different skill levels participated in Sunday morning's event, presented by UnitedHealthcare, to raise money for research, education, and advocacy. In the end, they raised over $350,000. The climb helps support the over 1.4 million people living with lung disease in Illinois. Due to the weekend's dangerous weather, organizers had changed the original 1,600-step route and added portable misting fans. The heat, however, didn't stop the Firefighter Challenge as teams of firefighters climbed in full gear. The American Lung Association said it looks forward to next year's event and "continuing its commitment to improving lung health and preventing lung disease."
